Compare BAK & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | OCS |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | Brazil | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2002 | N/A |
| Metric | BAK | OCS |
|---|---|---|
| Price | $4.92 | $27.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.40 | ★ $40.43 |
| AVG Volume (30 Days) | ★ 1.8M | 298.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $418.43 |
| Revenue Next Year | $6.45 | $892.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $14.00 |
| 52 Week High | $4.30 | $30.68 |
| Indicator | BAK | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 72.14 | 48.93 |
| Support Level | $3.35 | $19.00 |
| Resistance Level | N/A | $29.23 |
| Average True Range (ATR) | 0.24 | 0.99 |
| MACD | 0.05 | -0.38 |
| Stochastic Oscillator | 92.48 | 20.42 |
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.